Cannabinoids in Parkinson's Disease
The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436333/ https://www.ncbi.nlm.nih.gov/pubmed/28861502 http://dx.doi.org/10.1089/can.2017.0002 |
_version_ | 1783237379792830464 |
---|---|
author | Stampanoni Bassi, Mario Sancesario, Andrea Morace, Roberta Centonze, Diego Iezzi, Ennio |
author_facet | Stampanoni Bassi, Mario Sancesario, Andrea Morace, Roberta Centonze, Diego Iezzi, Ennio |
author_sort | Stampanoni Bassi, Mario |
collection | PubMed |
description | The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (γ-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids and other receptor systems (transient receptor potential vanilloid type 1 cation channel, adenosine receptors, 5-hydroxytryptamine receptors). The improved knowledge, adding new interpretation on the biochemical interaction between cannabinoids and other signaling pathways, may contribute to develop new pharmacological strategies. A number of preclinical studies in different experimental Parkinson's disease (PD) models demonstrated that modulating the cannabinoid system may be useful to treat some motor symptoms. Despite new cannabinoid-based medicines have been proposed for motor and nonmotor symptoms of PD, so far, results from clinical studies are controversial and inconclusive. Further clinical studies involving larger samples of patients, appropriate molecular targets, and specific clinical outcome measures are needed to clarify the effectiveness of cannabinoid-based therapies. |
format | Online Article Text |
id | pubmed-5436333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Mary Ann Liebert, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54363332017-08-31 Cannabinoids in Parkinson's Disease Stampanoni Bassi, Mario Sancesario, Andrea Morace, Roberta Centonze, Diego Iezzi, Ennio Cannabis Cannabinoid Res Mini-Review The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (γ-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids and other receptor systems (transient receptor potential vanilloid type 1 cation channel, adenosine receptors, 5-hydroxytryptamine receptors). The improved knowledge, adding new interpretation on the biochemical interaction between cannabinoids and other signaling pathways, may contribute to develop new pharmacological strategies. A number of preclinical studies in different experimental Parkinson's disease (PD) models demonstrated that modulating the cannabinoid system may be useful to treat some motor symptoms. Despite new cannabinoid-based medicines have been proposed for motor and nonmotor symptoms of PD, so far, results from clinical studies are controversial and inconclusive. Further clinical studies involving larger samples of patients, appropriate molecular targets, and specific clinical outcome measures are needed to clarify the effectiveness of cannabinoid-based therapies. Mary Ann Liebert, Inc. 2017-02-01 /pmc/articles/PMC5436333/ /pubmed/28861502 http://dx.doi.org/10.1089/can.2017.0002 Text en © Mario Stampanoni Bassi et al. 2017; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Mini-Review Stampanoni Bassi, Mario Sancesario, Andrea Morace, Roberta Centonze, Diego Iezzi, Ennio Cannabinoids in Parkinson's Disease |
title | Cannabinoids in Parkinson's Disease |
title_full | Cannabinoids in Parkinson's Disease |
title_fullStr | Cannabinoids in Parkinson's Disease |
title_full_unstemmed | Cannabinoids in Parkinson's Disease |
title_short | Cannabinoids in Parkinson's Disease |
title_sort | cannabinoids in parkinson's disease |
topic | Mini-Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436333/ https://www.ncbi.nlm.nih.gov/pubmed/28861502 http://dx.doi.org/10.1089/can.2017.0002 |
work_keys_str_mv | AT stampanonibassimario cannabinoidsinparkinsonsdisease AT sancesarioandrea cannabinoidsinparkinsonsdisease AT moraceroberta cannabinoidsinparkinsonsdisease AT centonzediego cannabinoidsinparkinsonsdisease AT iezziennio cannabinoidsinparkinsonsdisease |